These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 10418556)

  • 1. A dose-finding study of lenograstim (glycosylated rHuG-CSF) for peripheral blood stem cell mobilization during postoperative adjuvant chemotherapy in patients with breast cancer. Lenograstim/Breast Cancer Study Group.
    Narabayashi M; Takeyama K; Fukutomi T; Tokuda Y; Tajima T; Okumura A; Chou T; Sano M; Makino H; Igarashi T; Sasaki Y; Imoto S; Ogura M; Morishima Y; Murai H; Okamoto S; Ikeda T; Kasai M; Yokozawa T; Tobinai K
    Jpn J Clin Oncol; 1999 Jun; 29(6):285-90. PubMed ID: 10418556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dose-finding study of glycosylated G-CSF (Lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin's lymphoma.
    Takeyama K; Ogura M; Morishima Y; Kasai M; Kiyama Y; Ohnishi K; Mitsuya H; Kawano F; Masaki Y; Sasaki T; Chou T; Yokozawa T; Tobinai K;
    Jpn J Clin Oncol; 2003 Feb; 33(2):78-85. PubMed ID: 12629058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-escalating induction chemotherapy supported by lenograstim preceding high-dose consolidation chemotherapy for advanced breast cancer. Selection of the most acceptable regimen to induce maximal tumor response and investigation of the optimal time to collect peripheral blood progenitor cells for haematological rescue after high-dose consolidation chemotherapy.
    Van Hoef ME; Baumann I; Lange C; Luft T; de Wynter EA; Ranson M; Morgenstern GR; Yvers A; Dexter TM; Testa NG
    Ann Oncol; 1994 Mar; 5(3):217-24. PubMed ID: 7514434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of mobilization kinetics of circulating CD34+ cells between biweekly CHOP and dose-escalated CHOP with the prophylactic use of lenograstim (glycosylated rHuG-CSF) in aggressive non-Hodgkin's lymphoma. The lenograstim/Lymphoma Study Group.
    Itoh K; Ohtsu T; Sasaki Y; Ogura M; Morishima Y; Kasai M; Chou T; Yoshida K; Ohno T; Mizorogi F; Uike N; Sai T; Taniwaki M; Ikeda S; Tobinai K
    Leuk Lymphoma; 2000 Aug; 38(5-6):521-32. PubMed ID: 10953973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mobilization of peripheral blood stem cells by granulocyte-colony stimulating factors: comparison of a standard dose of glycosylated and mutated granulocyte-colony stimulating factor in non-Hodgkin's lymphoma patients following CHOP therapy.
    Takemoto Y; Wada H; Takatsuka H; Okamoto T; Kakishita E
    Drugs Exp Clin Res; 2000; 26(1):1-5. PubMed ID: 10761530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
    Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
    Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells.
    Vogel W; Kunert C; Blumenstengel K; Fricke HJ; Kath R; Sayer HG; Höffken K
    J Cancer Res Clin Oncol; 1998; 124(6):341-5. PubMed ID: 9692843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy.
    Bojko P; Pawloski D; Stellberg W; Schröder JK; Seeber S
    Ann Hematol; 2002 Sep; 81(9):522-8. PubMed ID: 12373354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Release of peripheral blood progenitor cells during standard dose cyclophosphamide, epidoxorubicin, 5-fluorouracil regimen plus granulocyte colony stimulating factor for breast cancer therapy.
    Venturini M; Del Mastro L; Melioli G; Balleari E; Garrone O; Pasquetti W; Bason C; Ghio R; Bruzzi P; Rosso R
    Cancer; 1994 Oct; 74(8):2300-6. PubMed ID: 7522948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma.
    Seymour AM; de Campos E; Thatcher N; De Greve J; Cunningham D; Howell A; Tueni E; Bron DG; Steward WP; Berdel WE
    Eur J Cancer; 1995 Dec; 31A(13-14):2157-63. PubMed ID: 8652235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy.
    Somlo G; Sniecinski I; ter Veer A; Longmate J; Knutson G; Vuk-Pavlovic S; Bhatia R; Chow W; Leong L; Morgan R; Margolin K; Raschko J; Shibata S; Tetef M; Yen Y; Forman S; Jones D; Ashby M; Fyfe G; Hellmann S; Doroshow JH
    Blood; 1999 May; 93(9):2798-806. PubMed ID: 10216073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor.
    Schwartzberg LS; Birch R; Hazelton B; Tauer KW; Lee P; Altemose R; George C; Blanco R; Wittlin F; Cohen J
    J Hematother; 1992; 1(4):317-27. PubMed ID: 1285381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mobilization of Philadelphia-negative peripheral blood progenitor cells with chemotherapy and rhuG-CSF in chronic myelogenous leukaemia patients with a poor response to interferon-alpha.
    Carella AM; Simonsson B; Link H; Lennard A; Boogaerts M; Gorin NC; Tomas-Martinez JF; Dabouz-Harrouche F; Gautier L; Badri N
    Br J Haematol; 1998 Apr; 101(1):111-8. PubMed ID: 9576191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial of two doses of cyclophosphamide with etoposide and G-CSF for mobilization of peripheral blood stem cells in 318 patients with stage II-III breast cancer.
    Schwartzberg LS; Weaver CH; Birch R; Manner C; Tauer K; Beeker T; Morgan-Ihrig C; MacAneny B; Leff R; Smith R; Hainsworth J; Greco T; Schwerkoske J; Murphy MN; Buckner CD
    J Hematother; 1998 Apr; 7(2):141-50. PubMed ID: 9597571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised study comparing peripheral blood progenitor mobilisation using intermediate-dose cyclophosphamide plus lenograstim with lenograstim alone.
    Karanth M; Chakrabarti S; Lovell RA; Harvey C; Holder K; McConkey CC; McDonald D; Fegan CD; Milligan DW
    Bone Marrow Transplant; 2004 Sep; 34(5):399-403. PubMed ID: 15273706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer.
    Somlo G; Sniecinski I; Odom-Maryon T; Nowicki B; Chow W; Hamasaki V; Leong L; Margolin K; Morgan R; Raschko J; Shibata S; Tetef M; Molina A; Berenson RJ; Forman SJ; Doroshow JH
    Blood; 1997 Mar; 89(5):1521-8. PubMed ID: 9057632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
    Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
    Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase.
    Olsson-Strömberg U; Höglund M; Björkholm M; Braide I; Carlson K; Gahrton G; Grimfors G; Hast R; Lerner R; Linder O; Ljungman P; Löfvenberg E; Malm C; Nilsson PG; Paul C; Rödjer S; Stenke L; Tidefeldt U; Turesson I; Uden AM; Wahlin A; Vilen L; Winqvist I; Zettervall O; Oberg G; Simonsson B
    Leuk Lymphoma; 2006 Sep; 47(9):1768-73. PubMed ID: 17064986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: a phase III, multicenter, randomized study.
    Gatzemeier U; Kleisbauer JP; Drings P; Kaukel E; Samaras N; Melo MJ; Cardenal F; Robinet G; Snijder RJ; von Pawel J; Palisses R
    Am J Clin Oncol; 2000 Aug; 23(4):393-400. PubMed ID: 10955871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenograstim-mobilized peripheral blood progenitor cells in volunteer donors: an open label randomized split dose escalating study.
    Basara N; Schmetzer B; Blau IW; Bischoff M; Günzelmann S; Kirsten D; Fauser AA
    Bone Marrow Transplant; 2000 Feb; 25(4):371-6. PubMed ID: 10723579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.